RIYADH: The Saudi Oncology Society and Gilead Sciences, a global biopharmaceutical company, have signed a memorandum of understanding for cooperation in research, clinical trials, medical education and scientific exchange to advance oncology care in the Kingdom.
The primary focus of the collaborative initiative is on education, research, awareness, optimizing treatment management and directing the audience to specialized health care professionals, a statement from the Gilead Sciences said.
These contributions aim to grow and improve the broader health care ecosystem in the Kingdom, with a special focus on oncology and addressing the unmet needs of cancer patients in the region.
According to the MoU, the agreement is initially set for a duration of three years with the potential for extension.
“Collaborating with leading oncologists and institutions in the region is part of our mission at Gilead as we drive clinical development and advance health care equity,” said Vitor Papao, general manager, Gilead Sciences Middle East. “Our partnership with the Saudi Oncology Society reflects that and our dedication to supporting health care professionals, bettering patient outcomes, and strengthening Saudi Arabia’s health care system. Gilead will continue working closely with local partners to ensure patients receive our ground-breaking therapies as quickly as possible.”
Dr. Meteb Al-Foheidi, chairperson, Saudi Oncology Society, said: “We are proud to embark on this transformative journey with Gilead Sciences to bolster our ongoing efforts to advance cancer research, clinical trials, and medical education in the Kingdom. As we sign the three-year agreement, we look forward to making meaningful contributions to the field of oncology and improving the broader health care landscape in Saudi Arabia.”
Gilead Sciences and SOS will hold regular meetings to align and roll out initiatives, ensuring they remain focused on their shared objectives.
